What is MLTX's current stock price?

MLTX (MoonLake Immunotherapeutics) is currently trading at $18.19 with a market cap of $1.34B.

What sector is MoonLake Immunotherapeutics in?

MoonLake Immunotherapeutics (MLTX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is MLTX a good stock to buy?

Analysts have a Buy consensus on MLTX with a price target of $28.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

MLTX MoonLake Immunotherapeutics

Healthcare

$18.19-1.52%ClosedMarket Cap: $1.34B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

5.10

P/S

0.00

EV/EBITDA

-4.58

DCF Value

$4.08

FCF Yield

-16.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-85.6%

ROA

-64.2%

ROIC

-75.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-69.7M	$—
Q4 null	$0.00	$-62.4M	$—
FY null	$0.00	$-227.3M	$—
Q3 null	$0.00	$-69.7M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$28.50

Target (Median)

$29.50

Target Range

$10.00 - $45.00

1 Strong Buy11 Buy2 Hold2 Sell0 Strong Sell

NeedhamBuy

2026-05-12

HC Wainwright & Co.Buy

2026-05-11

BTIGBuy

2026-03-30

Wolfe ResearchOutperform

2026-03-23

Rothschild & CoBuy

2026-03-19

Trading Activity

Insider Trades

View All

Bodenstedt Matthiasofficer: Chief Financial Officer

SellWed May 13

Bodenstedt Matthiasofficer: Chief Financial Officer

SellThu Apr 16

Santos da Silva Jorgedirector, officer: Chief Executive Officer

SellTue Apr 14

Santos da Silva Jorgedirector, officer: Chief Executive Officer

SellTue Apr 14

Bodenstedt Matthiasofficer: Chief Financial Officer

SellFri Apr 10

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.01

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Peers

MBX